Related Experiment Video
Updated: Sep 10, 2025

Using the E1A Minigene Tool to Study mRNA Splicing Changes
Published on: April 22, 2021
Context Matters: The Importance of a Comprehensive Genomic Region When Assessing the Therapeutic Potential of
Dyah W Karjosukarso1, Julia F Kiefmann1, Femke Bukkems1
1Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Abstract:
Mini/midigene splicing assays are often used to evaluate splicing modulation therapy, for example, employing antisense oligonucleotides (AONs). Twenty-five AONs targeting the splicing defect caused by a recurrent variant in ABCA4 (c.768G>T) were tested using a midigene containing a part of intron 5, exon 6, and a part of intron 6 of the ABCA4 gene. Surprisingly, almost all AONs showed high efficacy, complicating candidate selection. We hypothesized that the lack of genomic context may lead to a very accessible transcript for AONs. Indeed, the use of an ABCA4 maxigene that contains a part of intron 5, exon 6, parts of intron 6, and the genomic region between exons 7 and 11 allowed a clear distinction between efficacious and less efficacious AONs, corroborating the results we recently observed in patient-derived retinal cells. These underscore the necessity of a proper genetic context included in constructs used in splicing assays to assess the potential of splicing modulation therapy.
Insights
Mini/midigene splicing assays using antisense oligonucleotides (AONs) showed surprising efficacy for ABCA4 variants. A maxigene with full genomic context improved AON candidate selection for splicing modulation therapy.
Area of Science:
- Genetics
- Molecular Biology
- Ophthalmology
Background:
- Splicing modulation therapy, often using antisense oligonucleotides (AONs), is a promising approach for genetic disorders.
- Assessing AON efficacy typically involves mini/midigene splicing assays.
- A recurrent variant in the ABCA4 gene (c.768G>T) causes a splicing defect relevant to retinal diseases.
Purpose of the Study:
- To evaluate the efficacy of 25 AONs targeting the ABCA4 splicing defect.
- To investigate the impact of genomic context on AON efficacy in splicing assays.
- To determine the necessity of including proper genetic context in splicing assays for therapeutic assessment.
Main Methods:
- Testing 25 AONs in a midigene assay containing parts of ABCA4 intron 5, exon 6, and intron 6.
- Comparing AON efficacy in the midigene assay versus a maxigene assay with extended genomic context (introns 5-11).
- Corroborating findings with patient-derived retinal cells.
Main Results:
- Nearly all tested AONs demonstrated high efficacy in the midigene assay, hindering candidate selection.
- The maxigene assay, incorporating a larger genomic region, successfully differentiated between efficacious and less efficacious AONs.
- Results from the maxigene assay aligned with observations in patient-derived retinal cells.
Conclusions:
- The lack of extensive genomic context in mini/midigene assays may overestimate AON efficacy.
- Including a comprehensive genomic context in splicing assays is crucial for accurately assessing AONs for splicing modulation therapy.
- Maxigene assays provide a more reliable platform for selecting effective AON candidates for ABCA4-related disorders and potentially other genetic conditions.
Related Concept Videos
RNA Splicing
Ribosome Profiling
Applications of ribosome profiling
Ribosome profiling has many applications, including in vivo monitoring of translation inside a particular organ or tissue type and quantifying new protein synthesis levels.
The technique...
Alternative RNA Splicing
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...

